Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Girard

Showing results (101-110 of 396) with videos related to

Pageof 40
Sort By:
Bulletin Du Cancer|June 14, 2020
[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]Clémence Basse, Aurelie Swalduz, Matteo Giaj Levra, et al.
Lung Cancer (Amsterdam, Netherlands)|December 30, 2015
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutationsClaire Tissot, Sébastien Couraud, Ronan Tanguy, et al.
Clinical Lung Cancer|July 9, 2013
Physicians' knowledge and practice of lung cancer screening: a cross-sectional survey comparing general practitioners, thoracic oncologists, and pulmonologists in FranceSébastien Couraud, Nicolas Girard, Sylvie Erpeldinger, et al.
BMJ Open|February 6, 2023
Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort studyFiona Blackhall, Nicolas Girard, Alain Livartowski, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|October 16, 2019
The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in ChondrosarcomasJuliette Aury-Landas, Nicolas Girard, Eva Lhuissier, et al.
Plos One|May 24, 2014
3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cellsNicolas Girard, Céline Bazille, Eva Lhuissier, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|December 28, 2020
Second pulmonary resection for a second primary lung cancer: analysis of morbidity and survivalWalid Abid, Agathe Seguin-Givelet, Emmanuel Brian, et al.
The American Journal of Surgical Pathology|September 24, 2009
Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastasesNicolas Girard, Charuhas Deshpande, Christopher Lau, et al.
Chemical Communications (Cambridge, England)|July 15, 2014
Diastereoselective synthesis of novel aza-diketopiperazines via a domino cyclohydrocarbonylation/addition processPierre Regenass, Jean-François Margathe, André Mann, et al.
Future Oncology (London, England)|August 17, 2023
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamabAlexander Spira, Nicolas Girard, Matthew Krebs, et al.
Pageof 40

Showing results (101-110 of 396) with videos related to

Sort By:
Pageof 40
Bulletin Du Cancer|June 14, 2020
[Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management]Clémence Basse, Aurelie Swalduz, Matteo Giaj Levra, et al.
Lung Cancer (Amsterdam, Netherlands)|December 30, 2015
Clinical characteristics and outcome of patients with lung cancer harboring BRAF mutationsClaire Tissot, Sébastien Couraud, Ronan Tanguy, et al.
Clinical Lung Cancer|July 9, 2013
Physicians' knowledge and practice of lung cancer screening: a cross-sectional survey comparing general practitioners, thoracic oncologists, and pulmonologists in FranceSébastien Couraud, Nicolas Girard, Sylvie Erpeldinger, et al.
BMJ Open|February 6, 2023
Treatment patterns and outcomes among patients with small-cell lung cancer (SCLC) in Europe: a retrospective cohort studyFiona Blackhall, Nicolas Girard, Alain Livartowski, et al.
Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology|October 16, 2019
The Antitumoral Effect of the S-Adenosylhomocysteine Hydrolase Inhibitor, 3-Deazaneplanocin A, is Independent of EZH2 but is Correlated with EGFR Downregulation in ChondrosarcomasJuliette Aury-Landas, Nicolas Girard, Eva Lhuissier, et al.
Plos One|May 24, 2014
3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cellsNicolas Girard, Céline Bazille, Eva Lhuissier, et al.
European Journal of Cardio-Thoracic Surgery : Official Journal of the European Association for Cardio-Thoracic Surgery|December 28, 2020
Second pulmonary resection for a second primary lung cancer: analysis of morbidity and survivalWalid Abid, Agathe Seguin-Givelet, Emmanuel Brian, et al.
The American Journal of Surgical Pathology|September 24, 2009
Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastasesNicolas Girard, Charuhas Deshpande, Christopher Lau, et al.
Chemical Communications (Cambridge, England)|July 15, 2014
Diastereoselective synthesis of novel aza-diketopiperazines via a domino cyclohydrocarbonylation/addition processPierre Regenass, Jean-François Margathe, André Mann, et al.
Future Oncology (London, England)|August 17, 2023
A plain language summary of the results from the group of patients in the CHRYSALIS study with EGFR exon 20 insertion-mutated non-small-cell lung cancer who received amivantamabAlexander Spira, Nicolas Girard, Matthew Krebs, et al.
Pageof 40